natgillin/translations-raw huggingface dataset:
Genvoya bør ikke administreres sammen med lægemidler, som indeholder tenofoviralafenamid, tenofovirdisoproxil, lamivudin eller adefovirdipivoxil, der anvendes til behandling af infektion med HBV (se pkt. 
Genvoya should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of HBV infection (see section 4.5).
Samtidig administration med Genvoya kan føre til øgede plasmakoncentrationer af sildenafil og tadalafil, hvilket kan føre til bivirkninger associeret med PDE-5hæmmeren. 
Co-administration with Genvoya may result in increased plasma concentrations of sildenafil and tadalafil, which may result in PDE-5 inhibitor-associated adverse reactions.
Der foreligger ingen farmakokinetiske data om elvitegravir, cobicistat, emtricitabin eller tenofoviralafenamid hos patienter med nyresygdom i slutstadiet (estimeret CrCl < 15 ml/min), som ikke er i kronisk hæmodialyse. 
There are no pharmacokinetic data on elvitegravir, cobicistat, emtricitabine or tenofovir alafenamide in patients with end stage renal disease (estimated CrCl < 15 mL/min) not on chronic haemodialysis.
Hos patienter med samtidig infektion med hiv og HBV I et klinisk studie med hiv-inficerede, virologisk supprimerede patienter med samtidig infektion med kronisk hepatitis B, som fik Genvoya i 48 uger (GS-US-292-1249, n = 72), var 2 patienter kvalificerede til resistensanalyse. 
In a clinical study of HIV virologically suppressed patients co-infected with chronic hepatitis B, who received Genvoya for 48 weeks (GS-US-292-1249, n = 72), 2 patients qualified for resistance analysis.
- colchicin 
colchicine
Den gennemsnitlige stigning fra baseline i CD4+ celletal ved uge 48 var 224 celler/mm3. 
The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm3.
Efter skift til Genvoya forblev 90 % (45/50) af patienterne supprimerede (hiv 1-rna < 50 kopier/ml) ved 48 uger. 
After switching to Genvoya, 90% (45/50) of patients remained suppressed (HIV-1 RNA < 50 copies/mL) at Week 48.
Genvoya 150 mg/150 mg/200 mg/10 mg filmovertrukne tabletter Elvitegravir/cobicistat/emtricitabin/tenofoviralafenamid 
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Det gennemsnitlige CD4+ celletal ved baseline var 427 celler/mm3 (interval 0-1.360), og 13 % havde et CD4+ celletal på < 200 celler/mm3. 
The mean baseline CD4+ cell count was 427 cells/mm3 (range 0-1,360) and 13% had a CD4+ cell count < 200 cells/mm3.
Patienterne i kohorte 1 havde en gennemsnitsalder på 15 år (interval: 12 til 17 år), 44 % var mænd, 12 % var asiater, og 88 % var sorte. 
Patients in Cohort 1 had a mean age of 15 years (range 12 to 17), were 44% male, 12% Asian, and 88% Black.
• tenofovirdisoproxil 
• tenofovir disoproxil
ANTIARYTMIKA Digoxin (0,5 mg enkeltdosis)/ Cobicistat (150 mg flerdosis) 
ANTIARRHYTHMICS Digoxin (0.5 mg single dose)/ Cobicistat (150 mg multiple doses)
Ud af isolater af hiv 1 fra 12 patienter med resistensudvikling i Genvoya-gruppen var de mutationer, der opstod, M184V/I (n = 11) og K65R/N (n = 2) i RT og T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) og 
Of the HIV-1 isolates from 12 patients with resistance development in the Genvoya group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) and N155H (n = 2) in integrase.
Samtidig administration af Genvoya kan føre til øgede plasmakoncentrationer af DOAK-præparatet, hvilket kan føre til en øget blødningsrisiko. 
Co-administration with Genvoya may result in increased plasma concentrations of the DOAC, which may lead to an increased bleeding risk.
I studie GS-US-292-1825 blev virkning og sikkerhed af Genvoya evalueret i et ublindet klinisk studie med én behandlingsarm, hvor 55 hiv 1-inficerede voksne med nyresygdom i slutstadiet (eGFRCG < 15 ml/min) i kronisk hæmodialyse i mindst 6 måneder, inden de skiftede til Genvoya. 
In Study GS-US-292-1825, the efficacy and safety of Genvoya were evaluated in a single-arm, open-label clinical study in which 55 HIV-1 infected adults with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis for at least 6 months before switching to Genvoya.
Ældre Dosisjustering af Genvoya er ikke nødvendig hos ældre patienter (se pkt. 
Elderly No dose adjustment of Genvoya is required in elderly patients (see sections 5.1 and 5.2).
Ex vivo-studier af kaniner og in vivo-studier af hunde tyder på, at cobicistat har et lavt potentiale for QT-forlængelse, og kan forlænge PR-intervallet let og reducere den venstre ventrikelfunktion ved koncentrationer, der er mindst 11 gange højere end den humane eksponering ved den anbefalede daglige dosis på 150 mg. I et humant klinisk studie af 35 raske personer blev der udført ekkokardiogrammer ved baseline og efter personerne fik 150 mg cobicistat én gang daglig i mindst 15 dage og de indikerede ingen klinisk signifikant ændring i venstre ventrikelfunktion. 
Ex vivo rabbit studies and in vivo dog studies suggest that cobicistat has a low potential for QT prolongation, and may slightly prolong the PR interval and decrease left ventricular function at concentrations at least 11-fold higher than the human exposure at the recommended 150 mg daily dose.
Det er ukendt, om cobicistat, emtricitabin eller tenofoviralafenamid er hæmmere af andre UGT-enzymer. 
It is not known whether cobicistat, emtricitabine, or tenofovir alafenamide are inhibitors of other UGT enzymes.
dihydroergotamin, ergometrin, ergotamin (anvendes til at behandle migræne hovedpine) cisaprid (anvendes til at lindre visse maveproblemer) perikon (Hypericum perforatum, et naturlægemiddel, der anvendes til depression og angst) eller lægemiddel, der indeholder det lovastatin, simvastatin (anvendes til at sænke kolesterol i blodet) pimozid, lurasidon (anvendes til at behandle unormale tanker og følelser) sildenafil (når det anvendes til at behandle pulmonal arteriel hypertension - en lungesygdom, der gør det vanskeligt at trække vejret) oralt administreret midazolam, triazolam (anvendes til at hjælpe dig med at sove og/eller lindre angst) 
cisapride (used to relieve certain stomach problems) St. John's wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it lovastatin, simvastatin (used to lower blood cholesterol) pimozide, lurasidone (used to treat abnormal thoughts or feelings) sildenafil (when used to treat pulmonary arterial hypertension - a lung disease that makes breathing difficult) orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety)
Gennemsnitsalderen var 50 år (interval: 28-67), 92 % af patienterne var mænd, 69 % var hvide, 18 % var sorte, og 10 % var asiater. 
The mean age was 50 years (range 28-67), 92% of patients were male, 69% were White, 18% were Black, and 10% were Asian.
Koncentrationer af disse immunosupprimerende midler kan øges ved administration af cobicistat. 
Concentrations of these immunosuppressant agents may be increased when administered with cobicistat.
Gennemsnitlig % ændring af farmakokinetiske parametre for elvitegravira 
Mean % change of elvitegravir pharmacokinetic parametersa
EC50-værdierne for tenofoviralafenamid var i intervallet fra 2,0 til 14,7 nM. Tenofoviralafenamid viste antiviral aktivitet i cellekultur mod alle hiv 1-grupperne (M, N og O), herunder undertype A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,10 til 12,0 nM) og viste stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 0,91 til 2,63 nM). 
The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM).
Dosismodifikationer er ikke nødvendige ved samtidig administration af Genvoya. 
Dose modifications are not necessary when administered in combination with Genvoya.
Samtidig administration af rifabutin, en kraftig CYP3Ainducer, kan reducere plasmakoncentrationerne af cobicistat og elvitegravir signifikant, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens. 
Co-administration of rifabutin, a potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Delte tabletter må ikke gemmes. 
Do not store the split tablet.
Tre patienter havde virologisk svigt ved uge 48. 
Three patients had virologic failure at Week 48; there was no virologic resistance detected to Genvoya.
Isolater af hiv 1 med nedsat følsomhed for tenofoviralafenamid udtrykker en K65R-mutation i hiv 1 RT. 
HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.
Ved uge 144 havde 83,1 % (197/237 patienter) stadig hiv 1-rna < 50 kopier/ml, efter de var skiftet til Genvoya. 
At Week 144, 83.1% (197/237 patients) maintained HIV-1 RNA < 50 copies/mL after switching to Genvoya.
Ved uge 48 havde 92 % af patienterne (66/72) stadig hiv-1 RNA < 50 kopier/ml efter skift til Genvoya. 
At Week 48, 92% of patients (66/72) maintained HIV-1 RNA < 50 copies/mL after switching to Genvoya.
ORALE ANTIKONCEPTIVA Drospirenon/ethinylestradiol (3 mg/0,02 mg enkelt dosis)/cobicistat (150 mg én gang dagligt) 
ORAL CONTRACEPTIVES Drospirenone/Ethinyloestradiol (3 mg/0.02 mg single dose)/ Cobicistat (150 mg once daily)
I studie GS-US-292-1515 blev virkningen og sikkerheden af Genvoya evalueret i et ublindet studie af hiv 1-inficerede, virologisk supprimerede unge i alderen 12 til 18 år, der vejede ≥ 35 kg (n = 50). 
In Study GS-US-292-1515, the efficacy and safety of Genvoya were evaluated in an open-label study in HIV-1 infected, virologically suppressed adolescents between the ages of 12 and 18 years, weighing ≥ 35 kg (n = 50).
Polyethylenglycol (E1521) Talcum (E553b) 
Polyvinyl alcohol (E1203) Titanium dioxide (E171) Polyethylene glycol (E1521) Talc (E553b)
Nogle lægemidler må ikke administreres sammen med Genvoya (se pkt. 
Some medicinal products should not be co-administered with Genvoya (see sections 4.3 and 4.5).
Gennemsnitlig CD4+ celletal ved baseline var 697 celler/mm3 (interval 79-1.951). 
The mean baseline CD4+ cell count was 697 cells/mm3 (range 79-1,951).
Koncentrationer af pitavastatin kan øges ved administration af elvitegravir og cobicistat. 
Concentrations of pitavastatin may be increased when administered with elvitegravir and cobicistat.
Oralt administreret midazolam (2,5 mg enkeltdosis)/Tenofoviralafenamid (25 mg én gang daglig) 
Orally administered midazolam (2.5 mg single dose)/ Tenofovir alafenamide (25 mg once daily)
Anvendelsen af Genvoya bør ledsages af anvendelse af sikker kontraception (se pkt. 
The use of Genvoya should be accompanied by the use of effective contraception (see sections 4.4 and 4.5).
Koncentrationer af clarithromycin og/eller cobicistat kan ændres ved samtidig administration af Genvoya. 
Concentrations of clarithromycin and/or cobicistat may be altered with co-administration of Genvoya.
Intravenøst administreret midazolam (1 mg enkeltdosis)/Tenofoviralafenamid (25 mg én gang daglig) 
Intravenously administered midazolam (1 mg single dose)/ Tenofovir alafenamide (25 mg once daily)
Ændringer i målinger af knoglemineraltæthed 
Changes in measures of bone mineral density
Der rådes til forsigtighed og klinisk overvågning ved samtidig administration. 
Caution is warranted and clinical monitoring is recommended during the co-administration.
Patienter, som skiftede til Genvoya, opretholdt en forbedret renal sikkerhedsprofil efter 96 ugers behandling sammenlignet med dem, som forblev på et tenofovirdisoproxil-baseret regime. 
An improved renal safety profile was maintained through Week 96 in patients who switched to Genvoya compared with those who stayed on a tenofovir disoproxil-containing regimen.
Det gennemsnitlige CD4+ celletal ved baseline var 664 celler/mm3 (interval 126-1.813). 
The mean baseline CD4+ cell count was 664 cells/mm3 (range 126-1,813).
Desuden blev der forbigående observeret en K70E-mutation i hiv 1 RT. Isolater af hiv 1 med K65R-mutation har en lav grad af nedsat følsomhed for abacavir, emtricitabin, tenofovir og lamivudin. 
HIV-1 isolates with the K65R mutation have low-level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine.
Buprenorphin/Naloxon (16/4 til 24/6 mg)/Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig) 
Buprenorphine/Naloxone (16/4 to 24/6 mg)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
Triazolam metaboliseres primært af CYP3A. 
Triazolam is primarily metabolised by CYP3A.
Gilead Sciences Slovakia s.r.o. 
Slovenská republika Gilead Sciences Slovakia s.r.o.
Midazolam metaboliseres primært af CYP3A. 
Midazolam is primarily metabolised by CYP3A.
Koncentrationer af ketoconazol og/eller cobicistat kan øges ved samtidig administration af Genvoya. 
Concentrations of ketoconazole and/or cobicistat may increase with co-administration of Genvoya.
Imidlertid metaboliseres emtricitabin ikke signifikant af leverenzymer, så påvirkningen af nedsat leverfunktion bør være begrænset. 
The pharmacokinetics of emtricitabine have not been studied in patients with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Ved uge 48 havde 81,8 % (45/55 patienter) stadig hiv 1-rna < 50 kopier/ml, efter de var skiftet til Genvoya. 
At Week 48, 81.8% (45/55 patients) maintained HIV-1 RNA < 50 copies/mL after switching to Genvoya.
I studie GS-US-292-0106 blev virkningen, sikkerheden og farmakokinetikken af Genvoya evalueret i et ublindet studie af hiv 1-inficerede, behandlingsnaive unge i alderen 12 til < 18 år, der vejede ≥ 35 kg (n = 50) i kohorte 1, og hos virologisk supprimerede børn i alderen 8 til < 12 år, der vejede > 25 kg (n = 23) i kohorte 2. 
In Study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of Genvoya were evaluated in an open-label study in HIV-1 infected, treatment-naïve adolescents between the ages of 12 to < 18 years, weighing ≥ 35 kg (n = 50) in Cohort 1, and in virologically suppressed children between the ages of 8 to < 12 years, weighing > 25 kg (n = 23) in Cohort 2.
Ketoconazol (200 mg to gange daglig)/Elvitegravir (150 mg én gang daglig)2 
Ketoconazole (200 mg twice daily)/ Elvitegravir (150 mg once daily)2
Ved baseline, var median CD4+ celletal 969 celler/mm3 (interval: 603 til 1421), og median C4+ % var 39 % (interval: 30 til 51 %). 
At baseline, median CD4+ cell count was 969 cells/mm3 (range: 603 to 1,421), and median CD4+% was 39% (range: 30 to 51%).
Dosisjustering af sofosbuvir/velpatasvir/voxilaprevir og Genvoya er ikke nødvendig ved samtidig administration. 
No dose adjustment of sofosbuvir/velpatasvir/voxilaprevir and Genvoya is warranted upon co-administration.
 Hvis De tager nogen af disse lægemidler, må De ikke tage Genvoya. 
 If you are taking any of these medicines, do not take Genvoya and tell your doctor immediately.
Gennemsnitsændringen fra baseline i CD4+ celletal og procentdel ved 48 uger var henholdsvis -90 celler/mm3 og -1,3 %. 
The mean change from baseline in CD4+ cell count and percentage at Week 48 was -90 cells/mm3 and -1.3%, respectively.
Koncentrationer af telithromycin og/eller cobicistat kan ændres ved samtidig administration af Genvoya. 
Concentrations of telithromycin and/or cobicistat may be altered with co-administration of Genvoya.
Der blev ikke observeret nogen klinisk relevante forskelle i farmakokinetikken for elvitegravir eller cobicistat hos patienter med moderat nedsat leverfunktion og hos personer med normal leverfunktion. 
No clinically relevant differences in elvitegravir or cobicistat pharmacokinetics were observed between patients with moderate hepatic impairment and subjects with normal hepatic function.
Ved baseline var median CD4+ celletal 742 celler/mm3 (interval: 255 til 1246) og median CD4+ % var 34 % (interval: 21 til 53 %). 
At baseline, median CD4+ cell count was 742 cells/mm3 (range: 255 to 1,246) and median CD4+% was 34% (range: 21 to 53%).
• tenofoviralafenamid, et antiretroviralt lægemiddel, der kaldes en nukleotid-revers transkriptase-hæmmer (NtRTI) 
• tenofovir alafenamide, an antiretroviral medicine known as a nucleotide reverse transcriptase inhibitor (NtRTI)
FTCa TAFb TFVb 
TAFb TFVb EVGe COBIe FTCe TAFf
Samtidig administration af Genvoya og lovastatin og simvastatin er kontraindiceret (se pkt. 
Co-administration of Genvoya and lovastatin and simvastatin is contraindicated (see section 4.3).
Sikkerheden og virkningen af Genvoya blev evalueret i det ublindede studie GS-US-292-1249 hos voksne patienter med samtidig infektion med hiv-1 og kronisk hepatitis B. 69 ud af de 72 patienter havde tidligere fået tenofovirdisoproxil-baseret antiretroviral behandling. 
In open-label Study GS-US-292-1249, the efficacy and safety of Genvoya were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior tenofovir disoproxil-containing antiretroviral therapy.
NARKOTISKE ANALGETIKA Methadon (80-120 mg)/Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig) 
NARCOTIC ANALGESICS Methadone (80-120 mg)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
Dosisjustering af ledipasvir/sofosbuvir og Genvoya er ikke nødvendig ved samtidig administration. 
No dose adjustment of ledipasvir/sofosbuvir and Genvoya is warranted upon co-administration.
Ætiologien anses dog for at være multifaktoriel (anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højere Body Mass Index (BMI)). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
a n = 24 unge b n = 23 unge c AUClast d n = 15 unge e n = 19 voksne f n = 539 (TAF) eller 841 (TFV) voksne 
f n = 539 (TAF) or 841 (TFV) adults.
Samtidig administration af Genvoya kan føre til øgede plasmakoncentrationer af salmeterol, hvilket er forbundet med risikoen for alvorlige eller livstruende bivirkninger. 
Co-administration with Genvoya may result in increased plasma concentrations of salmeterol, which is associated with the potential for serious or life-threatening adverse reactions.
• emtricitabin, et antiretroviralt lægemiddel, der kaldes en nukleosid-revers transkriptase hæmmer (NRTI) 
• emtricitabine, an antiretroviral medicine known as a nucleoside reverse transcriptase inhibitor
Norgestimat (0,180/0,215 mg én gang daglig)/Ethinylestradiol (0,025 mg én gang daglig)/Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig)4 
Norgestimate (0.180/0.215 mg once daily)/ Ethinyloestradiol (0.025 mg once daily)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)4
Den rapporterede tidsperiode før sådanne opstår, er imidlertid variabel, og kan opstå mange måneder efter påbegyndelse af behandlingen (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).
Der blev ikke observeret nogen klinisk relevante forskelle i farmakokinetikken for elvitegravir, cobicistat eller tenofoviralafenamid hos patienter med nyresygdom i slutstadiet i kronisk hæmodialyse sammenlignet med hos patienter med normal nyrefunktion. 
No clinically relevant differences in elvitegravir, cobicistat, or tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal disease on chronic haemodialysis as compared to those with normal renal function.
Da cobicistat er til stede kan samtidig administration af Genvoya føre til øgede plasmakoncentrationer af dette lægemiddel, hvilket er forbundet med risikoen for alvorlige og/eller livstruende bivirkninger. 
Due to the presence of cobicistat, co-administration with Genvoya may result in increased plasma concentrations of this medicinal product, which is associated with the potential for serious or life-threatening adverse reactions.
Gennemsnitsændringen fra baseline i CD4+ celletal og procentdel ved 48 uger var henholdsvis -43 celler/mm3 og -0,1 %. 
The mean change from baseline in CD4+ cell count and percentage at Week 48 was -43 cells/mm3 and -0.1%, respectively.
Tabletten må ikke tygges eller knuses. 
Do not chew or crush the tablet.
Hiv 1-rna < 20 kopier/ml 
HIV-1 RNA < 20 copies/mL Treatment difference
Samtidig administration af Genvoya og triazolam er kontraindiceret (se pkt. 
Co-administration of Genvoya and triazolam is contraindicated (see section 4.3).
Norgestimat (0,180/0,215/0,250 mg en gang dagligt)/ethinylestradiol (0,025 mg en gang dagligt)/ emtricitabin/ tenofoviralafenamid (200/25 mg en gang dagligt)6 
Norgestimate (0.180/0.215/0.250 mg once daily)/ Ethinyloestradiol (0.025 mg once daily)/ Emtricitabine/Tenofovir alafenamide (200/25 mg once daily)6
Behandling med cobicistat og elvitegravir under graviditet medfører lavere eksponering for elvitegravir (se pkt. 
Treatment with cobicistat and elvitegravir during pregnancy results in lower elvitegravir exposure (see sections 4.4 and 5.2).
Der skal udføres klinisk overvågning ved samtidig administration med Genvoya. 
Clinical monitoring should be made upon co-administration with Genvoya.
Mave-tarm-kanalen Meget almindelig: 
Gastrointestinal disorders Very common:
Samtidig administration af Genvoya og oralt administreret midazolam er kontraindiceret (se pkt. 
Co-administration of Genvoya and orally administered midazolam is contraindicated (see section 4.3).
Klinisk overvågning anbefales ved samtidig administration af Genvoya. 
Clinical monitoring is recommended upon co-administration of Genvoya.
Midazolam: AUC: ↔ 
Cobicistat: AUC: ↔
HMG CO-A-REDUKTASEHÆMMERE Rosuvastatin (10 mg enkeltdosis)/Elvitegravir (150 mg én gang daglig)/Cobicistat (150 mg én gang daglig) 
HMG CO-A REDUCTASE INHIBITORS Rosuvastatin (10 mg single dose)/ Elvitegravir (150 mg once daily)/ Cobicistat (150 mg once daily)
Atorvastatin: AUC: ↑160 % Cmin: NC 
Atorvastatin: AUC: ↑ 160% Cmin: NC Cmax: ↑ 132%
Kontakt lægen, før De tager dette lægemiddel, hvis lægen har fortalt Dem, at De ikke tåler visse sukkerarter. 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
I studier af behandlingsnaive patienter var Genvoya forbundet med en mindre påvirkning af renale sikkerhedsparametre (målt efter 144 ugers behandling ved estimeret glomerulær filtrationshastighed via Cockcroft-Gault-metoden, og forhold mellem protein og kreatinin i urinen efter 96 ugers behandling ved forhold mellem albumin og kreatinin i urinen) sammenlignet med E/C/F/TDF (se også pkt. 
Cockcroft-Gault method, and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF (see also section 4.4).
Koncentrationerne af rosuvastatin øges forbigående ved samtidig administration af elvitegravir og cobicistat. 
Concentrations of rosuvastatin are transiently increased when administered with elvitegravir and cobicistat.
Sådan skal De tage Genvoya 
How to take Genvoya
Andel (%) patienter med hiv 1-rna < 50 kopier/ml pr. undergruppe 
Missing data during window but on study drug Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by subgroup
0,4 % (95 % CI: -3,0 % til 3,8 %) 5,4 % (95 % CI: 1,5 % til 9,2 %) 
5.4% (95% CI: 1.5% to 9.2%)
Hiv 1-rna ≥ 50 kopier/mlc Ingen virologiske data ved uge 48- eller 144-vinduet 
No virologic data at Week 48 or 144 window Discontinued study drug due to AE or deathd